我們已在上線！進一步了解

Royalty Pharma

RPRX

市值 US$271億

60.96 USD

+1.34

2.25%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

60.96

0.00

0%

1天

2.25%

5天

6.87%

1個月

4.26%

3個月

4.15%

6個月

25.74%

今年迄今

56.87%

1年

67.75%

5年

64.67%

10年

36.99%

關於： Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

員工： 100

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 48.3%

中性 48.3%

負面 3.4%

Royalty Pharma declares fourth quarter 2026 dividend

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.

Royalty Pharma declares fourth quarter 2026 dividend

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Zacks Investment Research

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again

The Motley Fool

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates. Its approach provides an optimal way to gain exposure to solid returns with minimal downside risk.

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts

Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.

Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts

The Motley Fool

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program

NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.

Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program

Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Royalty Pharma to present at upcoming investor conferences

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

Royalty Pharma to present at upcoming investor conferences

查看新聞排名

價格圖表採用Lightweight Charts™實作